Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT02972580

Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD

Longitudinal prospective observational study. This is a 24-month study with the possibility of extending the data time points. Initially baseline, then 12 and 24 months follow up studies will be completed.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Duchenne Muscular Dystrophy Becker Muscular Dystrophy Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Genetic Diseases, X-Linked Muscular Diseases Muscular Disorders, Atrophic Muscular Dystrophies Muscular Dystrophy, Duchenne Musculoskeletal Diseases Nervous System Diseases Neuromuscular Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Nationwide Children's Hosptial

Columbus, Ohio, 43205, United States

About this study

Four cohorts are enrolled in this study. The target population is the cohort of genetically confirmed DMD/BMD female carriers (Cohort A). This cohort will consist of 150 DMD/BMD mothers who are somatic carriers of a mutation in the DMD gene. The data collected for this cohort will be compared to three control groups; Control Group B is a cohort of 50 DMD/BMD mothers who are NOT somatic carriers, Control Group C is a cohort of 50 age-matched healthy controls and Control Group D is a cohort of 25 genetically confirmed carriers who do not have an affected child. The inclusion of a Control Group B allows for a comparison to a group of mothers that share the emotional and cognitive burden of caring for an affected male without having the physical or cognitive risks of being a female carrier. The Control Group C offers robust data from an age-matched healthy cohort for purposes of comparison. Control Group D allows for comparison to a group of women that have the same physical or cognitive risks as the Cohort A female carriers, but do not have the same burden of care giving.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18 years
  • Cohort A requires a genetically confirmed mutation in the DMD gene with an affected child
  • Cohort B includes DMD/BMD mothers with NO somatic mutation in the DMD gene
  • Cohort C age-matched healthy controls with a normal CK level
  • Cohort D requires a genetically confirmed mutation in the DMD gene without an affected child
  • Able to complete testing in English
  • Able to consent

Exclusion criteria

  • Subjects with a contraindication to cardiac or skeletal muscle MRI
  • Subjects on heart failure medication at time of enrollment
  • Subjects on steroid treatment
  • Presence of an inherited neurologic disease or comorbidity that may affect their ability to complete this study
  • Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with the protocol required testing or procedures or compromise the subject's wellbeing, safety, or clinical interpretability

Treatment and study plan

Genetic characterization

Genetic

Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts

Primary outcomes

  1. Compromise of cardiac function based on Cardiac Magnetic Resonance Imaging

    Time frame: 2 years

    Cardiac function as compromised by evidence of scarring of cardiac muscles, particularly of the base of the left ventricle via cardiac MRI studies with gadolinium contrast.

Secondary outcomes

  1. Cardiac Function Assessment Treadmill SVO2

    Time frame: 2 years

    Stress on heart muscle measured by SVO2 (percentage of oxygen saturation in the blood of the pulmonary artery). SVO2 represents an average of all the venous oxygen saturation of major organs and tissues. This measure provides assessment of cardiopulmonary function and helps measure the degree of cardiac instability and can be an indicator of deterioration from normal.

  2. Physical Therapy Assessments Maximum Voluntary Isometric Contraction Testing

    Time frame: 2 Years

    MVICT measures strength of skeletal muscles by assessing the force generated by by individual muscles. The results can be compared to norms and deterioration can be assessed over time.

  3. Physical Therapy Assessments 6 Minute Walk Test

    Time frame: 2 years

    A timed test to assess distance walked in 6 minutes is very quantitative and can be assessed in comparison to normal controls. Deterioration over time can be clearly measured.

  4. Physical Therapy Assessments ACTIVE-seated

    Time frame: 2 Years

    Exploratory outcome quantifying upper extremity reaching ability using a custom-designed game telling how far the arm reaches in comparison to overall functional ability of the individual ability.

  5. Physical Therapy Assessments Time-to-Rise

    Time frame: 2 Years

    A timed-test to measure ability to rise from the floor is quantifiable and measuring over time tells if there is loss of function.

  6. Laboratory biomarkers - Creatine Kinase

    Time frame: 2 Years

    CK levels are an indicator of muscle breakdown.

  7. Laboratory biomarkers - C-Reactive Protein

    Time frame: 2 Years

    Pro-inflammatory marker indicating the degree of inflammation of muscle when there is muscle breakdown.

  8. Laboratory biomarkers - Interleukin-6

    Time frame: 2 Years

    Pro-inflammatory marker indicating the degree of inflammation of muscle when there is muscle breakdown.

  9. Laboratory biomarkers - Cortisol levels

    Time frame: 2 Years

    Hair cortisol levels measure stress levels as a means of understanding coping with disease.

  10. Cognitive Assessment

    Time frame: 2 Years

    Cognitive function measured by Wechsler Abbreviated Scale of Intelligence (WASI) provides a possible tool to measure disease awareness and establish if IQ level correlates with disease-related stress.

  11. Caregiver Stress

    Time frame: 2 Years

    Online self-report survey to assess stress burden on caregiver.

  12. Pulmonary function testing (PFTs)

    Time frame: 2 Years

    Stable or improved FVC

Sponsors and collaborators

Lead sponsor

Nationwide Children's Hospital

Other

Collaborators

  • Parent Project Muscular Dystrophy

Registry information

Official study title

Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD)

Important dates

Study start
2016
Primary completion
2030
Study completion
2030
First posted
Nov 23, 2016
Registry last updated
Aug 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.

Recruiting

The Duchenne Registry

NCT02069756

Becker Muscular Dystrophy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Washington D.C., District of Columbia, United States

View Trial Details